A first-in-class antibiotic, gepotidacin, matched first-line treatments in pivotal Phase 3 trials, reporting non-inferiority for uncomplicated UTIs and for urogenital gonorrhea regimens. If confirmed in broader regulatory review, it adds another option to the UTI/gonorrhea pipeline at a time when antimicrobial resistance pressures are mounting. At the diagnostics end, a systematic review evaluating CSF parameters for suspected bacterial meningitis reported high specificity for Gram stain (99%) but emphasized that sensitivity varies sharply by pathogen—especially low for Listeria. The paired stories underline the dual need: improved therapeutics plus more reliable decision support when test sensitivity depends on likely organisms.